These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 25848301

  • 1. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
    Scherer DJ, Nicholls SJ.
    Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301
    [Abstract] [Full Text] [Related]

  • 2. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y, Shapiro MD.
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [Abstract] [Full Text] [Related]

  • 3. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations.
    Hallén J, Sreeharan N.
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct 01; 4(4):237-242. PubMed ID: 30060063
    [Abstract] [Full Text] [Related]

  • 4. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES, McCormack PL.
    Am J Cardiovasc Drugs; 2014 Dec 01; 14(6):471-8. PubMed ID: 25428605
    [Abstract] [Full Text] [Related]

  • 5. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J, Anzalone D, Hilleman D, Catini J.
    Lipids Health Dis; 2016 Jul 22; 15(1):118. PubMed ID: 27444154
    [Abstract] [Full Text] [Related]

  • 6. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.
    Patel AA, Budoff MJ.
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr 22; 23(2):145-9. PubMed ID: 26825470
    [Abstract] [Full Text] [Related]

  • 7. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD, Munger MA.
    Ann Pharmacother; 2013 Nov 22; 47(11):1517-23. PubMed ID: 24259598
    [Abstract] [Full Text] [Related]

  • 8. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ, Zamorano JL, Parhofer KG.
    Pharmacol Ther; 2022 Sep 22; 237():108172. PubMed ID: 35304222
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN, Patel SM, Bhatt DL.
    Curr Opin Cardiol; 2019 Nov 22; 34(6):721-727. PubMed ID: 31464773
    [Abstract] [Full Text] [Related]

  • 11. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar 04; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M, Tokgozoglu L, Parhofer KG, Handelsman Y, Leiter LA, Landmesser U, Brinton EA, Catapano AL.
    Expert Rev Cardiovasc Ther; 2022 Aug 04; 20(8):609-625. PubMed ID: 35876118
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M, Brent Muhlestein J, Le VT, May HT, Roy S, Nelson JR.
    Clin Cardiol; 2018 Jan 04; 41(1):13-19. PubMed ID: 29365351
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Omega-3 fatty acids for cardiovascular event lowering.
    Kaur G, Mason RP, Steg PG, Bhatt DL.
    Eur J Prev Cardiol; 2024 Jun 03; 31(8):1005-1014. PubMed ID: 38169319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.